The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Cardiovascular Risk of Nonsteroidal Anti‐inflammatory Drugs and Classical and Selective Cyclooxygenase‐2 Inhibitors: A Meta‐analysis of Observational Studies
Open accessAbstract
The purpose of this study was to review the published evidence on the clinical use of nonsteroidal anti‐inflammatory drugs (NSAIDs) and to assess the cardiovascular risk (CVR) of cyclooxygenase‐2 inhibitors (coxibs), excluding aspirin, by means of a meta‐analytic procedure. A search was conducted on MEDLINE and EMBASE databases between October 1999 and June 2018. Cohort and case‐control studies showing CVR as relative risk (RR), odds ratio, hazard ratio, or incidence rate ratio associated with NSAIDs versus no treatment were selected. We estimated the pooled RR and the 95% confidence interval (CI) for all NSAIDs as a whole and individually. Eighty‐seven studies met the inclusion criteria. Overall, NSAIDs were found to be associated with a statistically significantly increased CVR (RR, 1.24 [95%CI, 1.19‐1.28]). The risk was slightly higher for coxibs (RR, 1.22 [95%CI, 1.17‐1.28]) as compared with nonselective NSAIDs (RR, 1.18 [95%CI, 1.12‐1.24]). Data analysis by drug disclosed that rofecoxib (RR, 1.39 [95%CI, 1.31‐1.47]), followed by diclofenac (RR, 1.34 [95%CI, 1.26‐1.42]) and etoricoxib (RR, 1.27 [95%CI, 1.12‐1.43]) were the NSAIDs associated with the highest CVR. Analysis by type of event showed that the highest risk corresponded to vascular events for both coxibs (RR, 2.18 [95%CI, 1.72‐2.78]) and nonselective NSAIDs (RR, 2.46 [95%CI, 2.00‐3.02]). The meta‐analysis results suggest that the use of the marketed coxibs celecoxib and etoricoxib would be related to a statistically significant CVR increase. Etoricoxib CVR could be higher than that for celecoxib. This increment would be similar to classical NSAID CVR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NSAIDs significantly increase the risk of cardiovascular adverse outcomes.93”
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006) · BMJ · doi:10.1136/bmj.332.7553.1302 · Cited by 1,445
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis
Trelle, S., Reichenbach, S., Wandel, S., Hildebrand, P., Tschannen, B., Villiger, P. M., Egger, M., & Juni, P. (2011) · BMJ · doi:10.1136/bmj.c7086 · Cited by 1,166
McGettigan, P., & Henry, D. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60011 · Cited by 1,096
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
McGettigan, P., & Henry, D. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001098 · Cited by 571
Hippisley-Cox, J., & Coupland, C. (2005) · BMJ · doi:10.1136/bmj.330.7504.1366 · Cited by 561
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
Ray, W. A., Stein, C. M., Daugherty, J. R., Hall, K., Arbogast, P. G., & Griffin, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11131-7 · Cited by 503
Mamdani, M., Juurlink, D. N., Lee, D. S., Rochon, P. A., Kopp, A., Naglie, G., Austin, P. C., Laupacis, A., & Stukel, T. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16299-5 · Cited by 435
Solomon, S. D., Wittes, J., Finn, P. V., Fowler, R., Viner, J., Bertagnolli, M. M., Arber, N., Levin, B., Meinert, C. L., Martin, B., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.764530 · Cited by 367
Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events
Chan, A. T., Manson, J. E., Albert, C. M., Chae, C. U., Rexrode, K. M., Curhan, G. C., Rimm, E. B., Willett, W. C., & Fuchs, C. S. (2006) · Circulation · doi:10.1161/circulationaha.105.595793 · Cited by 319
García Rodríguez, L. A., Tacconelli, S., & Patrignani, P. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.041 · Cited by 305
Gislason, G. H., Rasmussen, J. N., Abildstrom, S. Z., Schramm, T. K., Hansen, M. L., Fosbøl, E. L., Sørensen, R., Folke, F., Buch, P., Gadsbøll, N., et al. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.525 · Cited by 295
Arfè, A., Scotti, L., Varas-Lorenzo, C., Nicotra, F., Zambon, A., Kollhorst, B., Schink, T., Garbe, E., Herings, R., Straatman, H., et al. (2016) · BMJ · doi:10.1136/bmj.i4857 · Cited by 290
Johnsen, S. P. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.9.978 · Cited by 288
Mamdani, M., Rochon, P., Juurlink, D. N., Anderson, G. M., Kopp, A., Naglie, G., Austin, P. C., & Laupacis, A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.4.481 · Cited by 281
Solomon, S. D., Pfeffer, M. A., McMurray, J. J. V., Fowler, R., Finn, P., Levin, B., Eagle, C., Hawk, E., Lechuga, M., Zauber, A. G., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.636746 · Cited by 273
Laine, L., Curtis, S. P., Cryer, B., Kaur, A., & Cannon, C. P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60234-7 · Cited by 251
Lévesque, L. E., Brophy, J. M., & Zhang, B. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00113 · Cited by 249
Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction
Kimmel, S. E., Berlin, J. A., Reilly, M., Jaskowiak, J., Kishel, L., Chittams, J., & Strom, B. L. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-3-200502010-00005 · Cited by 222
Helin-Salmivaara, A. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl053 · Cited by 211
Feenstra, J., Heerdink, E. R., Grobbee, D. E., & Stricker, B. H. C. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.3.265 · Cited by 194
Antirheumatic drug use and the risk of acute myocardial infarction
Suissa, S., Bernatsky, S., & Hudson, M. (2006) · Arthritis Care & Research · doi:10.1002/art.22094 · Cited by 184
Andersohn, F., Suissa, S., & Garbe, E. (2006) · Circulation · doi:10.1161/circulationaha.105.602425 · Cited by 178
Solomon, D. H., Avorn, J., Stürmer, T., Glynn, R. J., Mogun, H., & Schneeweiss, S. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21887 · Cited by 173
Fosbøl, E. L., Folke, F., Jacobsen, S., Rasmussen, J. N., Sørensen, R., Schramm, T. K., Andersen, S. S., Rasmussen, S., Poulsen, H. E., Køber, L., et al. (2010) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.109.861104 · Cited by 167
Olsen, A. S., Gislason, G., McGettigan, P., Fosbøl, E. L., Sørensen, R., Hansen, M. L., Køber, L., Torp-Pedersen, C. T., & Lamberts, M. (2015) · JAMA · doi:10.1001/jama.2015.0809 · Cited by 157
Bernatsky, S., Hudson, M., & Suissa, S. (2005) · Rheumatology · doi:10.1093/rheumatology/keh610 · Cited by 154
Schmidt, M., Christiansen, C. F., Mehnert, F., Rothman, K. J., & Sørensen, H. T. (2011) · BMJ · doi:10.1136/bmj.d3450 · Cited by 153
Carman, W. J., Su, S., Cook, S. F., Wurzelmann, J. I., & McAfee, A. T. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2131 · Cited by 149
Ray, W. A., Varas‐Lorenzo, C., Chung, C. P., Castellsagué, J., Murray, K. T., Stein, C., Daugherty, J. R., Arbogast, P. G., & García‐Rodríguez, L. A. (2009) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.805689 · Cited by 145
Lindhardsen, J., Gislason, G., Jacobsen, S., Ahlehoff, O., Olsen, A. S., Madsen, O. R., Torp-Pedersen, C. T., & Hansen, P. R. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-203137 · Cited by 133
Olsen, A. S., Fosbøl, E. L., Lindhardsen, J., Folke, F., Charlot, M. G., Selmer, C., Olesen, J., Lamberts, M., Ruwald, M. H., Køber, L., et al. (2012) · Circulation · doi:10.1161/circulationaha.112.112607 · Cited by 113
Solomon, D. H., Glynn, R. J., Rothman, K. J., Schneeweiß, S., Setoguchi, S., Mogun, H., Avorn, J., & Stürmer, T. (2008) · Arthritis Care & Research · doi:10.1002/art.23911 · Cited by 104
Singh, G., Wu, O., Langhorne, P., & Madhok, R. (2006) · Arthritis Research & Therapy · doi:10.1186/ar2047 · Cited by 104
Abraham, N. S., EL‐SERAG, H. B., Hartman, C. M., Richardson, P., & Deswal, A. M. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03292.x · Cited by 103
Shin, J., Park, M.-J., Lee, S. H., Choi, S., Kim, M.-H., Choi, N., Lee, J., & Park, B. (2015) · BMJ · doi:10.1136/bmj.h3517 · Cited by 102
Huerta, C., Varas‐Lorenzo, C., Castellsagué, J., & Rodriguez, L. A. G. (2006) · Heart · doi:10.1136/hrt.2005.082388 · Cited by 102
Cyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs and the Risk of Ischemic Stroke
Andersohn, F., Schade, R., Suissa, S., & Garbe, E. (2006) · Stroke · doi:10.1161/01.str.0000226642.55207.94 · Cited by 98
Lamberts, M., Lip, G. Y. H., Hansen, M. L., Lindhardsen, J., Olesen, J. B., Raunsø, J., Olsen, A. S., Andersen, P. K., Gerds, T. A., Fosbøl, E. L., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1581 · Cited by 97
Søndergaard, K. B., Weeke, P. E., Wissenberg, M., Olsen, A. S., Fosbøl, E. L., Lippert, F. K., Torp-Pedersen, C. T., Gislason, G., & Folke, F. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw041 · Cited by 97
Goodson, N. J., Brookhart, A. M., Symmons, D. P. M., Silman, A. J., & Solomon, D. H. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.076760 · Cited by 94
Bäck, M., Yin, L., & Ingelsson, E. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr421 · Cited by 92
Stroke risk and NSAIDs: a systematic review of observational studies
Varas‐Lorenzo, C., Riera‐Guàrdia, N., Calingaert, B., Castellsagué, J., Pariente, A., Scotti, L., Sturkenboom, M., & Perez‐Gutthann, S. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2227 · Cited by 92
Cyclooxygenase Selectivity of Nonsteroidal Anti-inflammatory Drugs and Risk of Stroke
Haag, M. D. M. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.11.1219 · Cited by 83
Increased Risk of Stroke Associated With Nonsteroidal Anti-Inflammatory Drugs
Chang, C., Shau, W., Kuo, C.-W., Chen, S.-T., & Lai, M. (2010) · Stroke · doi:10.1161/strokeaha.110.585828 · Cited by 83
Use of Aspirin and Ibuprofen Compared With Aspirin Alone and the Risk of Myocardial Infarction
Patel, T. N., & Goldberg, K. C. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.8.852 · Cited by 79
Nonaspirin NSAIDs, Cyclooxygenase 2 Inhibitors, and the Risk for Stroke
Roumie, C. L., Mitchel, E. F., Kaltenbach, L. A., Arbogast, P. G., Gideon, P. S., & Griffin, M. R. (2008) · Stroke · doi:10.1161/strokeaha.107.508549 · Cited by 79
Hydrogen Sulfide Promotes Adipogenesis in 3T3L1 Cells
Tsai, C.-Y., Peh, M. T., Feng, W., Dymock, B. W., & Moore, P. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119511 · Cited by 76
Non‐steroidal anti‐inflammatory drug use and risk of venous thromboembolism
Schmidt, M., Christiansen, C. F., Horváth–Puhó, E., Glynn, R. J., Rothman, K. J., & Sørensen, H. T. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04354.x · Cited by 71
Current Use of Nonsteroidal Antiinflammatory Drugs and the Risk of Acute Myocardial Infarction
Fischer, L. M., Schlienger, R. G., Matter, C. M., Jick, H., & Meier, C. R. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.4.503.61021 · Cited by 70
The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction
Brophy, J. M., Lévesque, L. E., & Zhang, B. (2006) · Heart · doi:10.1136/hrt.2006.089367 · Cited by 69
de Abajo, F. J., Gil, M., García-Poza, P., Bryant, V., Oliva, B., Timoner, J., & García‐Rodríguez, L. A. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3617 · Cited by 67
Meta-Analysis: Cardiovascular Events Associated with Nonsteroidal Anti-inflammatory Drugs
Salpeter, S. R., Gregor, P., Ormiston, T. M., Whitlock, R. P., Raina, P. S., Thabane, L., & Topol, E. J. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.10.056 · Cited by 66
Roumie, C. L., Choma, N. N., Kaltenbach, L. A., Mitchel, E. F., Arbogast, P. G., & Griffin, M. R. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1820 · Cited by 66
Mallen, S. R., Essex, M. N., & Zhang, R. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.581274 · Cited by 61
Concomitant use of ibuprofen and paracetamol and the risk of major clinical safety outcomes
de Vries, F., Setakis, E., & van Staa, T. P. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03705.x · Cited by 60
Kohli, P., Steg, P. G., Cannon, C. P., Smith, S. C., Eagle, K. A., Ohman, E. M., Alberts, M. J., Hoffman, E., Guo, J., Simon, T., et al. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.08.017 · Cited by 60
van der Linden, M. W., van der Bij, S., Welsing, P. M. J., Kuipers, E. J., & Herings, R. M. C. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.087254 · Cited by 60
García-Poza, P., de Abajo, F. J., Gil, M., Chacón, A., Bryant, V., & García‐Rodríguez, L. A. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12855 · Cited by 55
Use of antidepressants and NSAIDs in relation to mortality in long‐term breast cancer survivors
Wernli, K. J., Hampton, J. M., Trentham‐Dietz, A., & Newcomb, P. A. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2064 · Cited by 51
Stroke risk and NSAIDs: an Australian population‐based study
Caughey, G. E., Roughead, E. E., Pratt, N. L., Killer, G. T., & Gilbert, A. L. (2011) · The Medical Journal of Australia · doi:10.5694/mja11.10055 · Cited by 49
Mangoni, A. A., Woodman, R. J., Gaganis, V., Gilbert, A. L., & Knights, K. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03627.x · Cited by 48
Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?
van Staa, T. P., Rietbrock, S., Setakis, E., & Leufkens, H. G. M. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01991.x · Cited by 47
Krijthe, B. P., Heeringa, J., Albert Hofman, D., Franco, O. H., & Stricker, B. H. C. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004059 · Cited by 47
Meta-Analysis of Nonsteroidal Anti-Inflammatory Drug Use and Risk of Atrial Fibrillation
Liu, G., Yan, Y., Zheng, X., Xu, Y.-L., Lü, J., Hui, R., & Huang, X. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.08.015 · Cited by 45
Impact of NSAIDS on Mortality and the Effect of Preexisting Coronary Artery Disease in US Veterans
Lee, T. A., Bartle, B., & Weiss, K. B. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.03.003 · Cited by 44
Vecchis, R. D., Baldi, C., Biase, G. D., Ariano, C., Cioppa, C., Giasi, A., Valente, L., & Cantatrione, S. (2014) · PubMed · Cited by 43
Chao, T., Liu, C., Chen, S., Wang, K.-L., Lin, Y., Chang, S., Lo, L., Hu, Y., Tuan, T., Wu, T.-J., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.09.058 · Cited by 43
Use of Non-Steroidal Antiinflammatory Drugs and Type-Specific Risk of Acute Coronary Syndrome
Bueno, H., Bardajı́, A., Patrignani, P., Martín‐Merino, E., & García‐Rodríguez, L. A. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.12.008 · Cited by 41
Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke
Ungprasert, P., Matteson, E. L., & Thongprayoon, C. (2015) · Stroke · doi:10.1161/strokeaha.115.011678 · Cited by 40
Varas‐Lorenzo, C., Castellsagué, J., Stang, M. R., Perez‐Gutthann, S., Aguado, J., & Rodríguez, L. A. G. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1815 · Cited by 38
Liu, S. S., Bae, J. J., Bieltz, M., Ma, Y., & Memtsoudis, S. G. (2012) · Regional Anesthesia & Pain Medicine · doi:10.1097/aap.0b013e31823354f5 · Cited by 36
ABRAHAM, N. S., Castillo, D. L., & Hartman, C. M. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03706.x · Cited by 35
Wu, L.-C., Leong, P., Yeo, K., Li, T., Wang, Y., Chiou, J., & Wei, J. C. (2016) · Medicine · doi:10.1097/md.0000000000004792 · Cited by 35
Pontes, C., Marsal, J. R., Elorza, J. M., Aragón, M., Prieto‐Alhambra, D., & Morros, R. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.12.011 · Cited by 34
McGettigan, P., Han, P., Jones, L., Whitaker, D., & Henry, D. A. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03121.x · Cited by 32
Barthélémy, O., Limbourg, T., Collet, J., Beygui, F., Silvain, J., Bellemain-Appaix, A., Cayla, G., Chastre, T., Baumgärtner, I., Röther, J., et al. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.06.015 · Cited by 30
Kim, J.-M., Lee, J., Shin, C. M., Lee, D. H., & Park, B. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000133 · Cited by 30
Nonaspirin Nonsteroidal Anti-inflammatory Drugs and Hemorrhagic Stroke Risk
Choi, N., Park, B., Jeong, S., Yu, K., & Yoon, B. (2008) · Stroke · doi:10.1161/strokeaha.107.497040 · Cited by 28
Lapi, F., Piccinni, C. P., Simonetti, M., Levi, M., Aprile, P. L., Cricelli, I., Cricelli, C. A., & Fanelli, A. (2015) · Internal and Emergency Medicine · doi:10.1007/s11739-015-1288-3 · Cited by 27
Spalding, W. M., Reeves, M. J., & Whelton, A. (2007) · American Journal of Therapeutics · doi:10.1097/01.pap.0000249930.01907.db · Cited by 25
Chen, Y.-R., Hsieh, F., Chang, C., Chi, N., Wu, H.-C., & Chiou, H. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.01.044 · Cited by 25
Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Outcomes in Women
Bavry, A. A., Thomas, F., Allison, M., Johnson, K., Howard, B. V., Hlatky, M. A., Manson, J. E., & Limacher, M. C. (2014) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000800 · Cited by 24
Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China
Li, C., Wang, X., Ji, H., Zhang, X. Y., Li, X. F., Wang, L. Z., Wang, C., Wang, Y.-F., Yang, R., Wang, G. C., et al. (2017) · Clinical Rheumatology · doi:10.1007/s10067-017-3596-7 · Cited by 24
Non‐steroidal anti‐inflammatory drugs and risk of pulmonary embolism
Biere‐Rafi, S., Nisio, M. D., Gerdes, V. E. A., Porreca, E., Souverein, P. C., de Boer, A., Buller, H. R., & Kamphuisen, P. W. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2130 · Cited by 24
Risk of ischaemic cardiovascular events from selective cyclooxygenase‐2 inhibitors in osteoarthritis
Cunnington, M. C., Webb, D., Qizilbash, N., Blum, D., Mander, A., Funk, M. J., & Weil, J. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1590 · Cited by 24
Hung, Y., Lin, L., Chen, C., Chiou, J., Wang, Y., Wang, P. Y., & Wei, J. C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179081 · Cited by 21
Cho, S., Kim, D., Won, S., Lee, J., Park, B., Jang, E. J., Bae, S., & Sung, Y. (2017) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2017.08.002 · Cited by 20
Preadmission use of nonaspirin nonsteroidal anti-inflammatory drugs and 30-day stroke mortality
Schmidt, M., Horváth–Puhó, E., Christiansen, C. F., Petersen, K. L., Bøtker, H. E., & Sørensen, H. T. (2014) · Neurology · doi:10.1212/wnl.0000000000001024 · Cited by 18
Søndergaard, K. B., & Gislason, G. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx267 · Cited by 18
Mangoni, A. A., Woodman, R. J., Gilbert, A. L., & Knights, K. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1945 · Cited by 16
Grimaldi‐Bensouda, L., Rossignol, M., Danchin, N., Steg, P. G., Bessede, G., Ovize, M., Cottin, Y., Autret‐Leca, E., Bénichou, J., Abenhaim, L., et al. (2011) · Heart · doi:10.1136/hrt.2011.222448 · Cited by 15
Thöne, K., Kollhorst, B., & Schink, T. (2017) · Drugs - Real World Outcomes · doi:10.1007/s40801-017-0113-x · Cited by 13
Chuang, S., Hsu, P., Lin, F., Huang, Y., Wang, G., Chang, W., & Tsai, H. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13558 · Cited by 11
Nonsteroidal Antiinflammatory Drug Use and Cardiovascular Risks After Coronary Stent Implantation
Schmidt, M., Pedersen, L. H., Mæng, M., Lassen, J. F., Lash, T. L., Nielsen, T. T., & Sørensen, H. T. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.5.458 · Cited by 11
Chu, C., Chou, P., Lin, C., Cheng, C., Tsai, C.-J., Lan, T., Huang, M.-W., & Nestadt, G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162239 · Cited by 9
Serrano, J. L. S., Tenías, J. M., Arias, Á., Carreras, M. I. M., & Gámez, J. C. V. (2015) · Revista Española de Salud Pública · doi:10.4321/s1135-57272015000600008 · Cited by 6
Analgesic, antiulcer, antithrombotic drugs and organ damage: a population-based case-control study.
Battelli, D., Riccardi, R., Piscaglia, A. C., Ml, S., Mussoni, L., Zani, A., Vitale, V., & Monachese, N. (2015) · PubMed · Cited by 6
Asociación entre consumo de antiinflamatorios no esteroideos e insuficiencia cardíaca congestiva
Laredo, L., Rodríguez, Á., Vargas, E., Moreno, A., Cruz, A., & García-Díaz, J. D. D. (2003) · Medicina Clínica · doi:10.1016/s0025-7753(03)73800-7 · Cited by 5
Wade, K. C., Ellenberg, J. H., Großer, T., Brensinger, C. M., Kimmel, S. E., & Hennessy, S. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31820350d3 · Cited by 3
Serrano, J. L. S., Tenías, J. M., Arias, Á., Ferrer, E. Z., Lluch, M., & Gamez, J. C. V. (2016) · International Journal of Pharmacology · doi:10.3923/ijp.2016.612.616 · Cited by 2
Research works printed but not linked: 3
- Higgins JPT, 2011, Manual Cochrane de revisionessistemáticas de intervenciones, Cochrane, 1
- Sanchez Serrano JL, 2015, Cardiovascular risk associated with the use of nonsteroidal anti‐inflammatory drugs, Rev Esp Salud Publica, 89, 607
- Gutiérrez Dávila JM, 2007, Texto de Cardiología [Cardiology Text], 1145
Cited by
Management of Osteoarthritis: Expert Opinion on NSAIDs
Magni, A., Agostoni, P., Bonezzi, C., Massazza, G., Menè, P., Savarino, V., & Fornasari, D. (2021) · Pain and Therapy · doi:10.1007/s40122-021-00260-1 · Cited by 201
Mallet, C., Desmeules, J., Pegahi, R., & Eschalier, A. (2023) · Journal of Pain Research · doi:10.2147/jpr.s393809 · Cited by 83
“NSAIDs significantly increase the risk of cardiovascular adverse outcomes.(93) No robust evidence supports an association between paracetamol and adverse cardiovascular outcomes (stroke or myocardial infarction) in patients with atherosclerotic heart diseases.”
BackgroundCurrent Nanoparticle-Based Technologies for Osteoarthritis Therapy
Jin, G. (2020) · Nanomaterials · doi:10.3390/nano10122368 · Cited by 75
Inclusion Complexes of Non-Steroidal Anti-Inflammatory Drugs with Cyclodextrins: A Systematic Review
Miranda, G. M., Santos, V. O. R. E., Bessa, J. R., Teles, Y. C. F., Yahouédéhou, S. C. M. A., Gonçalves, M. D. S., & Ribeiro‐Filho, J. (2021) · Biomolecules · doi:10.3390/biom11030361 · Cited by 63
Therapeutic implications of cyclooxygenase (COX) inhibitors in ischemic injury
Khan, H., Sharma, K., Kumar, A., Kaur, A., & Singh, T. G. (2022) · Inflammation Research · doi:10.1007/s00011-022-01546-6 · Cited by 62
Metadata
- Authors
- Martín Arias, L. H., Martín González, A., Sanz Fadrique, R., & Vazquez, E. S.
- Affiliations
- Centre for Drug Surveillance (CESME) School of Medicine, Valladolid University Valladolid Spain
- Department of Pharmacy Sagrado Corazón Hospital Valladolid Spain
- Centre for Drug Surveillance (CESME) School of Medicine, Valladolid University Valladolid Spain
- Pharmacology, School of Medicine, Oviedo University Oviedo Spain
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2018-09-11
- Volume
- 59
- Issue
- 1
- Pages
- 55-73
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2891937954
- Cited by
- 68
- References
- 107
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 10 · 2023: 7 · 2022: 12 · 2021: 9 · 2020: 10 · 2019: 6 · 2018: 1
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- The Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Consultation of the Doctoral Thesis Database (TESEO) (Ministerio de Educación, Cultura y Deporte) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Keywords
- cardiovascular risk, nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, rofecoxib, diclofenac, etoricoxib, celecoxib, cardiovascular adverse events, vascular events, drug safety, relative risk, observational studies, non-selective NSAIDs
- MeSH terms
- Celecoxib, Etoricoxib, Anti-Inflammatory Agents, Non-Steroidal, Cardiovascular Diseases, Humans, Risk Factors, Cohort Studies, Case-Control Studies, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
